EVALUATION OF ANTIDEPRESSANT ACTIVITY OF TAPENTADOL IN SWISS ALBINO MICE
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i8.17129Keywords:
Antidepressant, Tapentadol, Swiss albino miceAbstract
Objective: The aim of this study is to evaluate the antidepressant activity of tapentadol using forced swimming test (FST) and tail suspension test (TST) experimental models.
Methods: A total of 36 Swiss albino mice (18 for each experimental model) were divided into 3 groups of 6 animals each. In both the experimental models, Group I received normal saline – 10 ml/kg (Control group), Groups II and III given tapentadol 20 mg/kg and tapentadol 40 mg/kg, respectively, for 7 days, intraperitoneally. On day 7, the drugs were given 40 minutes before conducting the experiment. The duration of immobility was noted and compared among all the 3 groups. The observations were analyzed using analysis of variance and Tukey's post-hoc test.
Results: The duration of immobility was significantly decreased in both the experimental models. Tapentadol groups when compared to control group showed statistically significant values, and better results were obtained with tapentadol 20 mg/kg groups in both the models. The mean duration of Immobility was 34.67 seconds in FST model and 101.00 seconds in TST model when treated with tapentadol 20 mg/kg compared to 102.33 seconds in FST control and 141 seconds in TST control groups. FST model demonstrates greater antidepressant efficacy of tapentadol (p<0.00) than with TST model (p<0.04).
Conclusion: Tapentadol showed significant antidepressant activity at the dose of 20 mg/kg. The results should be further confirmed by animal studies with different experimental models for the evaluation of depression and by human clinical studies, and if found effective, tapentadol can be preferred for patients with chronic pain, such as cancer pain.
Downloads
References
Hyman S, Chisholm D, Kessler R, Patel V, Ford WH. Mental disorders. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease Control Priorities in Developing Countries. 2nd ed. New York: Oxford University Press for the World Bank; 2006. p. 605-25.
Sadock BJ, Sadock VA, editors. Kaplan and Sadock’s Comprehensive Text Book of Psychiatry. 8th ed., Vol. 1 Philadelphia, PA: Lippincott William & Wilkins; 2004. p. 1625-6.
Anonymous. Depression, National Institute of Mental Health. Available from: http://www.nimh.nih.gov/health/publications/depression/depression booklet.pdf. [Last accessed on 2013 Nov 08].
Barrett K, Brooks H, Boitano S, Barman S. Ganong’s Review of Medical Physiology. 23rd ed. New York: McGraw Hill; 2010.
Rafieian-Kopaei M, Sewell RD. Newer antidepressants: Analgesic and relative mono amine reuptake inhibitor potency. Pham Pharmacol 1994;46:1088.
Harris NL. Chronic pain and depression. Aust Fam Physician 1999;28(1):36-9.
Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl J Med 19881;319(6):348-53.
Nekovarova T, Yamamotova A, Vales K, Stuchlik A, Fricova J, Rokyta R. Common mechanisms of pain and depression: Are antidepressants also analgesics? Front Behav Neurosci 2014;8:99.
Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, et al. (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)- phenol hydrochloride (tapentadol HCL): A novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323(1):265-76.
Kataria BC, Mehta DS, Chhaiya SB. Approval of new nervous system drugs in India compared with the US and EU. Int J Pharm Pharm Sci 2012;4(4):705-9.
Urani A, Roman FJ, Phan VL, Su TP, Maurice T. The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001;298(3):1269-79.
Vogel HG. Drug Discovery and Evaluation: Pharmacological Assays. 3rd ed. Germany: Springer; 2008.
Ramakrishna S, Gurusiddappa SK, Jambulingappa KL. A study of antinociceptive effect of venlafaxine in albino mice. Int J Basic Clin Pharmacol 2017;6:184-8.
Sanji N, Jyothi CH, Dinakar KR, Vidya HK. Evaluation of antidepressant activity of tramadol in Swiss albino mice compared to desipramine. Int J Pharm Res Health Sci 2015;3(1):538-43.
Nasare NV, Banerjee BD, Deshmukh PS, Mediratta PK, Ahmed RS, Saxena AK, et al. The impact of pharmacogenetics on adverse drug reactions to predict the efficacy of tramadol monotherapy for the treatment of post herpetic neuralgia patients. Int J Pharm Pharm Sci 2014;6(11):89-96.
Iyer SK, Mohan G, Ramakrishnan S, Theodore S. Comparison of tapentadol with tramadol for analgesia after cardiac surgery. Ann Card Anaesth 2015;18(3):352-60.
Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 2005;48(2):252-63.
Muth-Selbach U, Hermanns H, Driehsen C, Lipfert P, Freynhagen R. Racemic intrathecal mirtazapine but not its enantiomers acts anti-neuropathic after chronic constriction injury in rats. Brain Res Bull 2009;79(1):63-8.
Singh VP, Jain NK, Kulkarni SK. On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Res 2001;915(2):218-26.
Anjaneyulu M, Chopra K. Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin induced diabetic mice. Eur J Pharmacol 2006;538(1-3):80-4.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
